Insights

Strategic Partners ElevateBio’s role as a technology-driven advanced therapy CDMO with capabilities in cell therapies, gene edited therapies, RNA therapies, and mRNA vaccines positions it as a versatile manufacturing partner for biopharma across discovery to commercialization. Target potential clients seeking end-to-end development and scalable cGMP manufacturing, including companies expanding into new modalities.

New Site Expansion Expansion into Pittsburgh alongside readiness of the Waltham site for its first commercial product signals capacity growth and geographic diversification. This presents sales opportunities with sponsors needing regional risk mitigation, supply chain resilience, and dual-site manufacturing capabilities.

Leadership & Quality Appointment of a Chief Operating Officer to oversee operations and quality at multiple sites underscores a focus on compliant manufacturing and robust quality systems. Leverage this to appeal to partners prioritizing rigorous regulatory readiness, scalable QA processes, and audit-ready manufacturing environments.

Recent Collaborations Manufacturing agreement with Kyverna Therapeutics for miv-cel across U.S. commercial and global clinical supply demonstrates external demand for ElevateBio’s capabilities in CAR T-cell therapy manufacturing. Target similar cell therapy developers seeking scalable, multi-market supply solutions.

Innovation & Data Active science and product development activity, including an expanded gene editing platform, AI discovery, and LNP delivery showcased at industry forums, indicates a continuous innovation pipeline. Use this to engage partners exploring next-gen modalities and differentiated manufacturing services backed by cutting-edge tech.

Similar companies to ElevateBio

ElevateBio Tech Stack

ElevateBio uses 8 technology products and services including IBM Cognos Analytics, Twitter Ads, NetSuite, and more. Explore ElevateBio's tech stack below.

Media & News

ElevateBio's Email Address Formats

ElevateBio uses at least 4 email formats:
ElevateBio Email FormatsExamplePercentage
FLast@elevate.bioJDoe@elevate.bio
83%
First.Last@elevate.bioJohn.Doe@elevate.bio
9%
FL@elevate.bioJD@elevate.bio
5%
First@elevate.bioJohn@elevate.bio
3%

Frequently Asked Questions

What is ElevateBio's official website and social media links?

Minus sign iconPlus sign icon
ElevateBio's official website is elevate.bio and has social profiles on LinkedIn and Crunchbase.

How much revenue does ElevateBio generate?

Minus sign iconPlus sign icon
As of October 2026, ElevateBio's annual revenue is estimated to be $250M - $500M.

What is ElevateBio's NAICS code?

Minus sign iconPlus sign icon
ElevateBio's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does ElevateBio have currently?

Minus sign iconPlus sign icon
As of October 2026, ElevateBio has approximately 447 employees across 2 continents, including North America and Europe. Key team members include Chief Scientific Officer: A. P., Chief Commercial Officer: L. L. and Vice President, Process Development: M. S. Explore ElevateBio's employee directory with LeadIQ.

What industry does ElevateBio belong to?

Minus sign iconPlus sign icon
ElevateBio operates in the Pharmaceutical Manufacturing industry.

What technology does ElevateBio use?

Minus sign iconPlus sign icon
ElevateBio's tech stack includes IBM Cognos Analytics, Twitter Ads, NetSuite, Microsoft Intune, Google Cloud, DocuSign, ServiceNow and Vimeo.

What is ElevateBio's email format?

Minus sign iconPlus sign icon
ElevateBio's email format typically follows the pattern of FLast@elevate.bio. Find more ElevateBio email formats with LeadIQ.

How much funding has ElevateBio raised to date?

Minus sign iconPlus sign icon
As of October 2026, ElevateBio has raised $1.2B in funding. The last funding round occurred on May 24, 2023 for $401M.
ElevateBio logo

ElevateBio

Pharmaceutical ManufacturingMassachusetts, United States201-500 Employees

ElevateBio is a technology-driven contract development and manufacturing organization that supports biopharmaceutical partners from discovery through commercialization in the advanced-therapy space. The company combines gene editing capabilities with cGMP manufacturing and specialized expertise to advance a range of genetic medicine modalities, including cell therapies and RNA-based approaches. By offering integrated development and manufacturing services, ElevateBio helps partners move therapies toward clinical and, potentially, commercial stages.

Based in Waltham, Massachusetts, ElevateBio employs hundreds of people and operates within the pharmaceutical manufacturing sector as an advanced-therapy CDMO. A recent development includes a collaboration with Sartorius to test the Eveo platform, reflecting ongoing expansion of its capabilities.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
201-500

Section iconFunding & Financials

  • $1.2B

    ElevateBio has raised a total of $1.2B of funding over 5 rounds. Their latest funding round was raised on May 24, 2023 in the amount of $401M as a Series D.

  • $250M - $500M

    ElevateBio's revenue is estimated to be in the range of $250M - $500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.